Topical corticosteroid phobia may lead to poor adherence, resulting in persistent disease and escalation to systemic agents. The aim of this paper was to review current literature to assess topical steroid phobia prevalence, populations most at risk, reasons behind steroid phobia, and interventions to reduce it. A systematic search of PubMed, Ovid (Journals@Ovid, MEDLINE), ScienceDirect, and Web of Science was performed. Studies ranged from May 2000 to February 2021. In total, 37 articles met the inclusion criteria. There was inter-study variation in the way steroid phobia is defined, from concern to irrational fear. The worldwide prevalence of topical steroid phobia ranges from 31 to 95.7% and does not differ with patient race/ethnicity or dermatological condition. Female patients and caregivers, and those who have experienced side effects of topical corticosteroids are most likely to express steroid phobia. Reasons for steroid phobia include lack of education, fear of side effects, polypharmacy, misinformation, negative experience with topical steroids, and frequently changing of clinics. Successful interventions to address steroid phobia include patient education in the form of educational videos followed by individualized oral education based on concerns, and demonstrations of application of topical steroids. Multiple interventions address topical corticosteroid phobia and improve adherence of topical corticosteroids in the management of dermatological conditions. Providers should screen patients for steroid phobia, especially in populations particularly at risk. Interventions using patient education should be individualized based on concerns expressed during screening. Further research should investigate if reducing steroid phobia can in fact improve long-term adherence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40257-021-00623-6 | DOI Listing |
Clin Cosmet Investig Dermatol
November 2024
Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China.
Objective: Topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE-4) inhibitors are three common topical anti-inflammatory agents for treating atopic dermatitis (AD). The purpose of our study was to understand Chinese dermatologists' perceptions and the factors influencing their choices of the three agents.
Methods: An online questionnaire survey was conducted between 25 July 2022 and 25 August 2022 among Chinese dermatologists.
J Affect Disord
January 2025
Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:
Malays Fam Physician
August 2024
MBBChBAO, MMed (Int. Med.), AdvMDerm, Department of Medicine, Faculty of Medicine, University Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia. Email:
Introduction: Skin barrier dysfunction is an important component of atopic dermatitis (AD) pathophysiology. Topical corticosteroids (TCSs) are the mainstay therapy, but steroid phobia is emerging due to potential side effects. We aimed to determine the short-term effect of clobetasone butyrate on patients with AD.
View Article and Find Full Text PDFJMIR Form Res
August 2024
Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon.
Background: Social media platforms like TikTok are a very popular source of information, especially for skin diseases. Topical steroid withdrawal (TSW) is a condition that is yet to be fully defined and understood. This did not stop the hashtag #topicalsteroidwithdrawal from amassing more than 600 million views on TikTok.
View Article and Find Full Text PDFBr J Dermatol
July 2024
Department of Dermatology, APHM, Marseille, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!